Clinical phase III study of YP-18 for febrile neutropenia

Trial Profile

Clinical phase III study of YP-18 for febrile neutropenia

Completed
Phase of Trial: Phase III

Latest Information Update: 18 Jul 2017

At a glance

  • Drugs Piperacillin/tazobactam (Primary)
  • Indications Febrile neutropenia
  • Focus Therapeutic Use
  • Sponsors Taiho Pharmaceutical
  • Most Recent Events

    • 30 Jun 2015 New trial record
    • 26 Jun 2015 As per a Taiho Pharmaceutical media release, this trial is one of the pivotal trials on which the MHLW Japan approval of piperacillin/tazobactam for use in Febrile Neutropenia is based upon.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top